Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) (NCT04566991)
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (DISH)
🩺 Plain-English Summary (8th-Grade Level)
Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals. This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.
Who can join: Review the eligibility criteria below.
Location: University of Michigan — Ann Arbor, Michigan
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Michigan — Ann Arbor, Michigan
📞 Contact the Study Coordinator
Phone: (734) 647-7960
Email: skoduri@med.umich.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Aneurysmal Subarachnoid Hemorrhage
- Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2) — Durham, North Carolina
- Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage — Boston, Massachusetts
- The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage — Birmingham, Alabama
- Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage — Louisville, Kentucky
- Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events — Gainesville, Florida
Explore by condition: All Aneurysmal Subarachnoid Hemorrhage clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.